Sempra Energy (NYSE:SRE) taking place in active move after eased up 0.44% to the trading price of $115.45 in latest session.
Southern California Gas Co., a subsidiary of Sempra Energy (NYSE:SRE), reported the successful installation of a novel bioreactor system that will be used to test power-to-gas technology at the U.S. Department of Energy’s National Renewable Energy Laboratory (NREL) in Golden, Colorado. Power-to-gas technology is a cutting-edge method of storing excess renewable energy. Last month, researchers at NREL’s Energy Systems Integration Facility (ESIF) in Golden, Colorado, installed a 25-foot tall bioreactor system, which will be used to produce renewable natural gas from excess renewable electricity using archaeamicroorganisms that consume hydrogen and carbon dioxide and emit methane.
“Power-to-gas technology can importantly increase the overall amount of renewable energy we use, by providing an economical method of storing excess solar-and wind-generated electricity,” said Jeff Reed, director of business strategy and advanced technology at SoCalGas. “And this technology takes advantage of existing infrastructure, and can hold excess renewables for days, weeks or months to shift solar from day to night, address weather patterns and even seasonal patterns.”
Its 52-week range quite noticeable, lower range was $24.21% and hit highest level of $-3.93%. The overall volume in the last trading session was 105937 shares. The firm shares 50 day moving average were calculated -1.06%. The firm’s institutional ownership remained 85.60% while insider ownership included 0.10%.
Verastem, Inc. (NASDAQ:VSTM) trade at $4.59 by moved down -0.65% in most recent trading session with share volume of 103651. Verastem, Inc. (NASDAQ:VSTM) reported that the appointment of NgocDiep Le, MD, PhD, as Chief Medical Officer. Dr. Le will be responsible for overseeing the development strategy and activities for Verastem’s core assets, duvelisib and defactinib.
“Diep is a highly accomplished physician-scientist who possesses exceptional scientific, medical, and organizational skills, with a unique background that includes a dual focus on hematologic oncology and immuno-oncology,” said Robert Forrester, President and Chief Executive Officer of Verastem. “She also brings extensive experience forging relationships with key opinion leaders and designing and executing successful clinical development programs. We are delighted to welcome Diep to the Verastem team and believe her contributions will be invaluable as we work toward our goal of filing a New Drug Application (NDA) for duvelisib with the U.S. Food and Drug Administration (FDA) during the first half of 2018.”
Dr. Le commented, “Given my previous work on phosphoinositide 3-kinase (PI3K) and focal adhesion kinase (FAK) inhibitors at GlaxoSmithKline (GSK), I have been following the development of duvelisib and defactinib for some time, and I am excited by each asset’s potential for new treatment options for patients with cancer. With the recently declared top-line results from the Phase 3 DUO study in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Verastem has created positive momentum with duvelisib, and I look forward to leveraging this with key opinion leaders and other stakeholders as we work to prepare and file the duvelisib NDA. For defactinib, I will be working with the entire team to ensure its rapid advancement in combination with immunotherapies and other anti-cancer agents for the treatment of a broad range of solid tumors.”
The share is moved forward to its percent change from 52-week low of 337.14% and hanging back from its percent change from 52-week high of -19.61%. Shares price moved down from its 50 days moving average with 8.46% and remote positively from 200 days moving average with 81.59%.
Shares of Xperi Corporation (NASDAQ:XPER) held volume of 88220 shares as compare to its average volume of 448.30 shares. Invensas Corporation, (NASDAQ:XPER) issued a statement giving an update on a nullity proceeding filed by Avago Technologies GmbH against a patent at issue in Invensas’ legal proceedings against Broadcom Ltd. and certain of its affiliates and distributors in Germany. On October 5, 2017, the German Federal Patent Court issued a notice giving its tentative view that the German part of Invensas’ EP 1 186 034 B1, a patent Broadcom has been adjudicated to infringe, may be invalid for various reasons. The Court made it clear that this was not its final decision, but instead was being issued “[i]n preparation for the oral hearing on 25 January 2018,… with no intention of anticipating the outcome of the oral hearing.” The Court’s statement is designed to guide the parties and focus their arguments in advance of the oral hearing. Invensas will make a further submission in response to the Court’s notice on December 6, 2017.
“We think the Court’s reasoning in its preliminary statement is flawed, and we look forward to having the opportunity to provide further briefing and arguments at the hearing in January,” said Jon Kirchner, the Company’s Chief Executive Officer. According to common German legal practice, in response to the preliminary statement Invensas has voluntarily agreed to abstain, at least temporarily, from enforcing the Regional Court of Mannheim’s judgments of infringement of the ‘034 Patent pending the nullity hearing. “We continue to believe the patent is valid and will be upheld at the hearing.”
XPER had a trade volume of 88220 shares as compared to average trading capacity of 448.30 shares. The firm has price to sales ratio of 3.86 and its price to book per share was 2.46. Similarly reduced performance for the quarter recorded as -30.23% and for the year was -41.17%, while the YTD performance remained at -48.70%.